lunes, 18 de abril de 2022

Study identifies Etravirine and Dolutegravir as effective entry inhibitors of wild-type and predominant variants of SARS-CoV-2

Study identifies Etravirine and Dolutegravir as effective entry inhibitors of wild-type and predominant variants of SARS-CoV-2
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)